Gs 441524 Powder: Can the active metabolite derived from the "miracle drug" Remdesivir become the core of the next generation of broad-spectrum antiviral drugs?

GS-441524 powder is a nucleoside analog prodrug developed by Gilead Sciences. Its chemical name is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carboxynitrile, with the molecular formula C₁₂H₁₃N₅O₄ and a molecular weight of 291.26 g/mol. It appears as a white to pale yellow powder, with a water solubility of approximately 10–20 mg/mL. Its solubility in DMSO is even higher. The purity of the active pharmaceutical ingredient must be ≥98% (HPLC) to ensure efficacy.

From the perspective of the molecular skeleton, GS-441524 is a deeply modified product of an adenosine analog. Its core structure consists of two parts: one is the ribosome (tetrahydrofuran ring), which retains the ribosome structure of the natural nucleoside, ensuring that it can be recognized and phosphorylated by cellular kinases; the other is the base part, in which the adenine of the natural adenosine is replaced with a 4-aminopyrrolo[2,1-f][1,2,4] triazine heterocycle, and a formonitrile group is introduced at the C2 position of the ribosome. These two modifications are the key to its activity.

A sophisticated imposter

The base moiety of GS-441524 is not naturally occurring adenine, but rather a 4-aminopyrrolo[2,1-f][1,2,4]triazine group. This system is key to GS-441524's ability to "deceive" viral RNA-dependent RNA polymerase. Compared to adenine, this modified base undergoes subtle changes in spatial configuration and hydrogen bonding ability, allowing it to be mistakenly recognized and utilized by viral polymerase, while simultaneously hindering chain synthesis after integration into the nascent RNA chain. This "fatal attraction" mechanism is the core idea behind the design of many nucleoside antiviral drugs.

Attached to this base is a β-D-furanose ring. However, the ribose moiety of GS-441524 has also undergone special modification. Unlike natural adenosine, the 1' carbon of the ribose in GS-441524 is linked to a base, rather than through a nitrogen atom, thus classifying it as a C-nucleoside. More importantly, the 2' carbon atom of its ribose is linked to a cyano group, rather than a hydroxyl or hydrogen atom as found in natural nucleosides. This 2'-cyano modification is the key structural basis for the broad-spectrum antiviral activity of GS-441524 and its prodrug remdesivir. This cyano group not only increases the molecule's metabolic stability but also forms additional interactions with key amino acid residues when binding to the active site of the viral RdRp, greatly enhancing the inhibitory effect. Molecular simulation studies show that this cyano group can insert into the active site of RdRp, forming hydrogen bonds with conserved residues, thereby firmly "locking" the polymerase and preventing it from further elongating the RNA chain.

From the perspective of medicinal chemists, the molecular structure of GS-441524 also implies "modifiability." Its molecule contains three hydroxyl groups and one primary amine group, providing abundant modification sites for prodrug design. For example, to improve its oral bioavailability, researchers protected these hydroxyl groups with ester groups, developing oral prodrugs such as GS-621763. Remdesivir itself is based on GS-441524, with a phosphoramide ester structure attached to the hydroxyl group of its ribose. The key difference lies in bypassing the rate-limiting first step of phosphorylation in vivo, directly releasing the monophosphorylated active form within cells. In short, GS-441524 is not only an effective antiviral molecule itself, but also an ideal "nucleus," providing chemists with a perfect platform for designing and optimizing next-generation antiviral drugs with better pharmacokinetic properties. From a pharmaceutical raw material perspective, compared to Remdesivir, which has complex synthetic steps requiring chiral separation, the chemical synthesis route of GS-441524 is shorter and significantly cheaper, paving the way for its large-scale production and wider application.

From rescuing cats to fighting COVID-19

The history of GS-441524's application is a legendary tale of moving from the "underground" to the "official" field. Long before Remdesivir gained global fame for treating COVID-19, GS-441524 had already demonstrated astonishing efficacy in the veterinary field, particularly in the treatment of feline infectious peritonitis (FIP).

Feline infectious peritonitis, caused by a mutation of feline coronavirus, was long considered an incurable disease for cats, with a near 100% mortality rate. Before 2019, veterinarians worldwide were virtually helpless against this disease. However, the advent of GS-441524 completely changed this situation. Research found that GS-441524, as an RNA polymerase inhibitor, can extremely effectively inhibit the replication of feline coronavirus. Numerous clinical cases and subsequent studies have shown that through approximately 12 weeks of daily subcutaneous or oral administration, GS-441524 can cure over 90% of affected cats, making this once incurable disease curable. For example, in clinical cases reported in domestic veterinary journals, all cats treated with GS-441524 as the main drug recovered and were discharged from the hospital. This success not only saved the lives of countless cats but also earned GS-441524 a very high reputation among pet owners and veterinarians, laying the groundwork for its application in the field of human antiviral therapy.

GS-441524 truly entered the global public eye as the active metabolite of remdesivir. Remdesivir was the first antiviral drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19. After entering the human body, remdesivir is rapidly hydrolyzed by esterases in plasma and tissues, converting it into GS-441524. GS-441524 then enters infected cells, undergoes three-step phosphorylation by intracellular phosphokinases, and is ultimately converted into an active triphosphate metabolite to inhibit the RNA replication of the SARS-CoV-2 virus. Although the clinical efficacy of remdesivir is controversial, the antiviral ability of its active metabolite, GS-441524, is undeniable. Research by Professor Zhang Xumu's team at Southern University of Science and Technology confirmed that GS-441524 can effectively inhibit SARS-CoV-2 replication in a dose-dependent manner in multiple cell lines, with its antiviral activity on the same order of magnitude as remdesivir, and with lower cytotoxicity.

Mechanism of action: Precision strike under a dual mechanism

For a long time, GS-441524 has been regarded as a classic nucleoside analog polymerase inhibitor, with its mechanism of action considered to be "single": after intracellular phosphorylation, it disguises itself as natural adenosine triphosphate (ATP) and competitively incorporates into the nascent RNA chain catalyzed by viral RNA-dependent RNA polymerase. Once incorporated, its unique chemical structure hinders the addition of subsequent nucleotides, leading to premature termination of RNA chain synthesis and thus blocking viral replication. However, with further research, scientists have discovered that the antiviral effects of GS-441524 go far beyond this; it actually possesses a "dual mechanism," which may be the underlying reason for its remarkable therapeutic efficacy.

A groundbreaking study published in *EMBO Reports* in 2024 revealed previously undiscovered immunomodulatory functions of GS-441524. Researchers used computer-aided molecular docking simulations to discover that GS-441524 can bind to the adenosine A2A receptor, with a predicted binding affinity even higher than its natural ligand—adenosine itself. Adenosine is an immunosuppressive molecule produced in large quantities at sites of inflammation and tissue damage. It suppresses the immune response and prevents excessive inflammation from damaging the body by activating the A2AR receptor on the surface of immune cells, sending a "stop attack" signal. However, in chronic viral infections or the tumor microenvironment, this mechanism can be exploited by viruses or tumor cells, leading to immune cell dysfunction and an inability to effectively clear pathogens.

This study confirms that GS-441524 can act as an A2AR antagonist both in vitro and in vivo, blocking the inhibitory effect of adenosine on immune cells. This means that GS-441524 can not only directly "attack" the virus, but also "liberate" the immune system "bound" by the virus, helping immune cells such as T cells to regain vitality and more effectively clear infected cells. Researchers found in a mouse model infected with SARS-CoV-2 that treatment with GS-441524 or remdesivir significantly enhanced the infiltration and function of CD8+ T cells in the lungs of mice, accelerating viral clearance. This "two-pronged" mode of action—inhibiting the virus while enhancing host immunity—perfectly explains why the efficacy shown by GS-441524 and its prodrug in preclinical and clinical studies may surpass simple in vitro antiviral activity. This also provides new insights into understanding the treatment of sequelae such as "long-term COVID-19," as immune regulation may be key to clearing the viral reservoir or restoring immune homeostasis.

The intracellular metabolism of GS-441524 is also quite complex. As a hydrophilic molecule, GS-441524 requires specific transport proteins to enter the cell, and then undergoes a three-step phosphorylation process catalyzed by intracellular kinases to produce its activity. The first phosphorylation step, catalyzed by adenosine kinase, is considered the rate-limiting step. This explains why its prodrug, remdesivir, is designed in a phosphoramide ester form. Remdesivir can bypass the rate-limiting first phosphorylation step, directly penetrate the cell membrane, and release monophosphorylated GS-441524 intracellularly, thus forming the active triphosphate metabolite more quickly and efficiently. However, remdesivir is unstable in plasma and is prone to premature hydrolysis to GS-441524. This creates an interesting balance: while remdesivir can efficiently deliver the "ammunition" into cells, it is prone to "prematurely detonating" in the bloodstream, transforming into GS-441524, which requires the first step of phosphorylation by cellular kinases. Therefore, different prodrug design strategies, such as the MeRDV currently under development, aim to improve plasma stability by optimizing the ester structure while maintaining high sensitivity to lung tissue hydrolases, in order to precisely deliver more active metabolites to target organs. This finding regarding prodrug and metabolism provides valuable data for pharmaceutical raw material experts, guiding the selection or development of the most suitable GS-441524 raw material form based on different therapeutic needs.

From optimized dosing to expanded indications, the "evolutionary path" of GS-441524

Even though GS-441524 has already achieved remarkable results, scientists have never stopped there. To date, research on GS-441524 is developing in a more diversified and refined direction, mainly focusing on the following three cutting-edge areas.

Development of long-acting sustained-release formulations

When treating diseases such as feline infectious peritonitis, GS-441524 typically requires daily administration for weeks or even months. This frequent dosing not only causes stress in animals but also increases the care burden on pet owners. To address this issue, researchers are actively exploring long-acting delivery systems for GS-441524. A recent study attempted to encapsulate GS-441524 in polylactic acid-glycolic acid copolymer nanoparticles to prepare an injectable sustained-release formulation. The drug-loaded nanoparticles prepared in this study have a particle size of approximately 216 nanometers and an encapsulation efficiency of up to 78%, enabling the sustained release of 92% of the drug over 7 days. More importantly, preliminary pharmacokinetic studies in cats showed that a single injection of 22 mg/kg of GS-PLGA NP resulted in a systemic exposure of 1.52 times over one week compared to daily injection of 4 mg/kg of free GS-441524, with significantly improved cellular uptake efficiency and anti-feline coronavirus efficacy. This breakthrough suggests that in the future, a single injection could provide stable treatment for up to a week or even longer, greatly improving patient compliance and quality of life.

Research and optimization of novel prodrugs

Remdesivir, as a phosphoramide prodrug of GS-441524, is limited to outpatient or mildly symptomatic use due to its intravenous administration. Developing novel prodrugs with high oral bioavailability and efficient conversion to their active form in target tissues is a current research hotspot. In addition to GS-621763 and MeRDV mentioned above, scientists are exploring the design of more prodrugs with innovative structures and multiple metabolic pathways, providing more flexible control over optimizing drug pharmacokinetic properties. Future prodrug design will be more precise; for example, by attaching specific targeting groups, drugs can be "navigated" to the "headquarters" of viral replication—the lungs or lymphatic system—achieving precise delivery and improving efficacy while reducing potential side effects from systemic exposure.

Continuous expansion of indications

The broad-spectrum antiviral activity of GS-441524 has indeed expanded its indications. Besides COVID-19 and feline infectious peritonitis (FIP), and the newly discovered canine distemper virus, its potential antiviral spectrum continues to expand. Multiple studies have confirmed its effectiveness against parainfluenza virus, respiratory syncytial virus, Lassa virus, and Ebola virus. More importantly, the discovery of its immunomodulatory function has opened a new door for expanding its indications. Since GS-441524 can enhance T cell function by antagonizing the A2A receptor, could it play a role in other diseases related to T cell exhaustion? Currently, research teams have designed and synthesized a series of novel nucleoside analogs based on the structural framework of GS-441524 as candidate drugs for treating COVID-19 and other coronavirus infections. Some of these compounds have entered preclinical research stages. The ultimate goal of these studies is not only to develop another anti-COVID-19 drug, but also to establish a "broad-spectrum antiviral drug library" based on the GS-441524 core, capable of rapidly responding to future emerging viral outbreaks.

Conclusion

From saving countless cats from peril to becoming a crucial weapon in the treatment of global pandemics, and now exhibiting an astonishing dual mechanism of action, the journey of GS-441524 is far from over. It demonstrates the qualities of an excellent drug molecule: ingenious structure, clear mechanism, broad application, and high versatility. Breakthroughs in long-acting nanoformulations are solving the "last mile" problem in clinical use; iterations of novel prodrugs aim to push efficacy and convenience to the extreme; and the continuous expansion of indications suggests its potential to shine in a wider range of human and animal health fields. The story of GS-441524 is a classic example of how an active metabolite can become the core of a potential next-generation antiviral drug, providing us with a reliable tool to combat future unknown viral threats.

Xi'an Faithful Biotechnology Co., Ltd. combines advanced production technology with a comprehensive quality assurance system to provide high-quality GS-441524 powder that meets international pharmaceutical standards. We are committed to providing highly competitive prices and comprehensive technical support, making us the preferred partner for healthcare institutions and researchers worldwide. Please contact our technical team (allen@faithfulbio.com) to learn how our products can improve your formulations.

References

1.Murphy, B. G., Perdigoto, A. L., Liu, H., & Pedersen, N. C. (2018). The nucleoside analog GS‑441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Veterinary Microbiology, 219, 226–233.

2.Zhang, L., Wang, Y., & Li, J. (2022). Binding adaptation of GS‑441524 diversifies macro domains and down‑regulates SARS‑CoV‑2 de‑MARylation capacity. Journal of Molecular Biology, 434(15), 167689.

3.Chen, L., Zhao, J., & Wu, Y. (2025). GS‑441524 as a broad‑spectrum antiviral agent: From preclinical studies to clinical development. Antiviral Research, 203, 105489.

4.Sun, C., Zhang, X., Chen, Y., et al. (2026). Application of LC–MS/MS in investigating the converted pathways of a novel prodrug of GS441524, to its active metabolite in vitro and in vivo. Microchemical Journal, 220, 116342. 

5.Monticone, G., Huang, Z., Mulfinger, L., et al. (2024). Novel immunomodulatory properties of adenosine analogs promote their antiviral activity against SARS-CoV-2. EMBO Reports, 25, 3547–3573.

6.Oliver-Guimera, A., Murphy, B. G., & Keel, M. K. (2025). The Nucleoside Analog GS-441524 Effectively Attenuates the In Vitro Replication of Multiple Lineages of Circulating Canine Distemper Viruses Isolated from Wild North American Carnivores. Viruses, 17(2), 150.

7.Agrawal, N., Almazan, F., & Perlman, S. (2020). Remdesivir and GS‑441524 inhibit SARS‑CoV‑2 replication in vitro and in vivo. Cell Research, 30(7), 579–588.